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The One Year Determinants of Patients Which Show The Cardiovascular
Mortality, Who were Hospitalized for Acute Decompense Heart Failure
Sati Sena Yıldız1, Pınar Soysal2, Mehmet Ali Çıkrıkçıoglu2
1Gökçebey Public Hospital _Internal Medicine Department, Zonguldak, 2Bezm-i Alem
Vakıf Gureba Research and Training Hospital, 2. Internal Medicine Clinic, _Istanbul
Aim: The presence of many blood count and biochemical parameters are known to
show mortality in acute decompensated heart failure. In our study, we aimed to ﬁnd
the best markers showing mortality.
Method: 176 patients hospitalized due to ADHF were enrolled. Treatment modalities
and comorbidities inﬂuencing leukocyte counts were excluded.Hemogram, ProBNP,
D-Dimer, cardiac troponins, biochemistry, sensitive C-reactive protein, urinanalysis
and echocardiography were obtained. Cardiovascular deaths at the end of the ﬁrst year
were determined.
Results: WBC and absolute neutrophil count were signiﬁcantly higher and absolute
lymphocyte and absolute eosinophil counts were signiﬁcantly lower in the deceased
patients than patients survived. Groups were similar in terms of monocyte counts.
BMI, ferritin, uric acid, free T3 (FT3), D-dimer, ProBNP, ejection fraction (EF),
albumin, systolic dysfunction, mitral regurgitation, hypotension, hyponatremia, acute
renal failure were signiﬁcantly different among dead and surviving patients. Logistic
regression analysis employing these variables showed that low BMI, low albumin,
low EF, hyponatremia, low absolute eosinophil count, and low FT3 as a whole were
responsible from the 81.8% of cardiovascular deaths. Death rate among patients with
an absolute eosinophil count of 20/mm3 was 4.8 fold higher than the patients with
an absolute eosinophil of >20/mm3.
Conclusıon: In our study, in ADHF, six levels associated with prognosis were worth
signiﬁcantly more than others: the EF Low, low BMI, hypoalbuminemia, free T3,
hyponatremia, eosinopeni. Eosinopenin is thought to be due to increased sympatho-
adrenarjik activty.
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Background and Aim: Galectin-3 is a new biomarker assumed to reﬂect cardiac
remodelling and ﬁbrosis in patients with heart failure. The factors that alter galectin-3
levels are unknown. In this study, we aimed to evaluate the relationship between
galectin-3 levels and echocardiographic parameters in symptomatic heart failure
patients.
Methods: Twenty eight patients with systolic heart failure (ejection fraction 35,
NYHA class II, III) and 17 age-matched controls with normal ventricular functions
were enrolled to the study. Echocardiographic measurements were noted and serum
samples were obtained for galectin-3 levels.
Results: The mean age of the patients was 64.710, 67% of the patients were male. Of
all patients, 9% had diabetes and 51% had hypertension. Most of the heart failure
patients (89%) had ischemic cardiomyopathy, 68% of them had NYHA II symptoms.
The mean galectin-3 levels were signiﬁcantly higher in heart failure patients compared
to control group (1.13 0.42 ng/ml vs. 0.60.26 ng/ml, p¼0.0001). There was no
signiﬁcant difference in galectin-3 levels between patients with NYHA II and NYHA III
symptoms (p¼0.53). There was a strong correlation between left atrium volume
(r¼0.39, p¼0.008), left ventricular end systolic diameter (r¼0.55, p¼0.0001), left
ventricular end diastolic diameter (r¼0.45, p¼0.002), left ventricular end systolic
volume (r¼0.58, p¼0.0001), left ventricular end diastolic volume (r¼0.46, p¼0.001),
left ventricular ejection fraction (r¼-0.58, p¼0.0001) and galectin-3 levels. Patients
were classiﬁed into three groups according to their galectin-3 tertiles (<0.68, 0.68-1.11,
>1.11 ng/ml). The number of male patients was signiﬁcantly higher in the third tertile
(p¼0.02). Left ventricular end systolic diameters (p¼0.0001), left ventricular end dia-
stolic diameters (p¼0.01), left ventricular end systolic volumes (p¼0.0001), and left
ventricular end diastolic volumes (p¼0.005) were increased in second and third tertiles.
Conclusıons: Galectin-3, a ﬁbrosis related biomarker, is elevated in patients with
symptomatic heart failure and has a strong correlation with increased left ventricular
volumes.
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Prognostic Role of Echocardiographic Parameters in Heart Failure Patients with
Incidental Massive Pleural Effusion Diagnosed During Echocardiographic
Evaluation
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Aim: The prognostic signiﬁcance of patients with heart failure complicated with
pleural effusions determined by means of echocardiography is lacking. Thus weC110 JACC Vosought to determine the prognostic signiﬁcance of transthoracic echocardiographic
parameters at heart failure patients with pleural effusion which was evaluated inci-
dentally during echocardiographic evaluation.
Methods: Between Jan 2002 and Dec 2012, total 151 patients with heart failure
suffered from pleural effusion analysed. All patients mortality data are derived from
registry center of Social Insurance Institution which ofﬁcially responsible for
recording all mortality data in Turkey. The diagnosis of patients’ pleural effusion
status were made during echocardiographic evaluation. Kaplan-Meir survival
rates were determined and subgroups were compared with log-rank test and Chi-
square test.
Results: Total 151 eligible patients were analysed. Mean age was 6016 with 97 men
(64.2%) and 54 women (35.8%). Mean duration of follow-up was 71.545.6 months.
Fifty-one patients (33.8%) died during this follow-up period. There was not a signif-
icant difference regarding age and sex between survivors and those had died during
follow-up. There were no prognostic signiﬁcance of left ventricular end diastolic
diameter, ejection fraction, mitral insufﬁciency, tricuspid insufﬁciency, and estimated
pulmonary artery pressure (p>0.05). However dilated left atrium diameter was found
to be associated with a poor prognosis (p¼0.04).
Conclusıon: Dilatation of the left atrium has a worse prognostic signiﬁcance in
patient with heart failure complicated with pleural effusion determined by means of
echocardiography. it is no seems to have prognostic signiﬁcance of other echocar-
diographic parameters incluiding left ventricular end diastolic diameter, ejection
fraction, mitral insufﬁciency, tricuspid insufﬁciency, and estimated pulmonary artery
pressure.PP-074
Galectin-3 in a Sample of Hospitalized Class IV NYHA Heart Failure Patients
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Aims: Galectin-3 is an emerging biomarker in heart failure (HF). Almost all data
on galectin-3 have been derived from post hoc analyses from randomized clinical
trials. Data from real-time populations addressing the distribution and usefulness of
galectin-3 are lacking. This study was conducted to determine the clinical and
biochemical correlates of galectin-3 in hospitalized class IV NYHA HF patients
admited for pharmacological therapy.
Methods and Results: We included 18 HF patients, with hypertension and ischemia
as main etiologies; patients were caucasian; median age 78 (mean age 7314);
7 males (38,9%),11 females (61,1%); 11 were in sinus rhythm and 7 in atrial ﬁbril-
lation; median BMI was 27, median creatinine 115 mmol/mL, median galectin-3 25.3
ng/mL. Median NT-proBNP was 10019 pg/ml. Galectin-3 was substantially elevated
in all patients, positively correlated with creatinine (Spearman Coefﬁcient of 0.54;
p¼0.02) but not with NTproBNP. Of our patients, concerning echocardiography data,
8 (44%) had HF with preserved (EF 50%) and 10 (56%) had HF with reduced EF
(EF < 50%). In the group with EF 50%, the median LVEDV was 111 ml and in the
group with EF<50% the median LVEDV was 167ml (p¼0.04); in the group with
EF 50%, the median LVESV was 48 ml and in the group with EF<50% the median
LVESV was 98ml (p<0.01). Galectin-3 was equally elevated in both HFPEF or
HFREF, and its correlations with creatinine, NT-proBNP, echo parameters of LV
(LVEDD, LVESD, LVEF) and LA (LA diameters and volumes) were comparable in
HFPEF and HFREF groups.
Conclusıons: Galectin-3 levels are elevated in all patients with HF, and galectin-3 was
positively correlated with creatinine but not with NT-proBNP. Galectin-3 was simi-
larly elevated in HFPEF and HFREF in this contemporary HF cohort.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
